Roth Capital reiterated a Buy rating and $50.00 price target on Sarepta Therapeutic (NASDAQ: SRPT) as the advisory meeting has ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

AdCom Changes Gives Sarepta Therapeutic (SRPT) Prep Time; Recommends Owning Into Briefing Doc ReleaseOctober 15, 2015 8:00 AM Sarepta Therapeutics (SRPT) Announces Tentative Scheduling of FDA Review for Eteplirsen in DMDOctober 14, 2015 12:44 PM Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular DystrophyOctober 14, 2015 12:43 PM Streetinsider.com's Hot Lunchtime Reads 10/14: (WMT) (ZFGN) (TRIP) (SRPT)October 14, 2015 12:35 PM Sarepta Therapeutics' (SRPT) Eteplirsen May Be Reviewed on Jan. 22 by FDA Panel - BloombergOctober 14, 2015 11:43 AM Sarepta's (SRPT) DMD drug may be reviewed by FDA panel in January - BloombergOctober 14, 2015 11:41 AM BioMarin's (BMRN) Drisparsen Advisory Committee Meeting Set for Nov. 24 October 14, 2015 9:16 AM